IXEMPRA Kit (ixabepilone) for Injection, for intravenous infusion only Initial U.S. Approval: 2007

Category: .

IXEMPRA Kit (ixabepilone) for Injection, for intravenous infusion only Initial U.S. Approval: 2007

INDICATIONS AND USAGE
• IXEMPRA, a microtubule inhibitor, in combination with capecitabine is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane.
• IXEMPRA as monotherapy is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline, a taxane, and capecitabine.
DOSAGE FORMS & STRENGTHS
• IXEMPRA for injection, 15 mg supplied with DILUENT for IXEMPRA, 8 mL
• IXEMPRA for injection, 45 mg supplied with DILUENT for IXEMPRA, 23.5 mL
Manufactured By: Bristol-Myers Squibb
Prescribing Information URL: Click Here

Access to IXEMPRA ® Kit (ixabepilone) for Injection: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is a pharmaceutical drug developed by Bristol-Myers Squibb as a chemotherapeutic medication for cancer.
On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. In November 2008, the EMEA has refused a marketing authorisation for Ixabepilone.
Ixabepilone is administered through injection, and is marketed under the trade name Ixempra.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.